Sunday, July 23, 2017 1:37:51 PM
Also the FDA is not requiring more data- there is no significant short term capital drain - there is no urgency to begin NDA or complete a deal. If it takes until yearend so be it.
Having said that I expect an announcement within 90 days as I believe interested players and their offers are on the table- and further delay is unlikely to enhance value significantly.!I believe SCLC trial not being released as part of non disclosure agreements with serious parties.
I am long- think a buyout likely- probably 3-4 dollar range- because we have no leverage. We can not bring this to market on our own. I hope and pray that multiple buyers are elevating the price but after experiencing astellas rape OCAT shareholders (like me), I believe an equitable valuation is unlikely.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM